Jannick A N Dorresteijn
About
Jannick A N Dorresteijn is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Surgery.
According to data from OpenAlex, Jannick A N Dorresteijn has authored 71 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cardiology and Cardiovascular Medicine, 26 papers in Economics and Econometrics and 23 papers in Surgery. Recurrent topics in Jannick A N Dorresteijn's work include Health Systems, Economic Evaluations, Quality of Life (26 papers), Lipoproteins and Cardiovascular Health (22 papers) and Blood Pressure and Hypertension Studies (15 papers). Jannick A N Dorresteijn is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (26 papers), Lipoproteins and Cardiovascular Health (22 papers) and Blood Pressure and Hypertension Studies (15 papers). Jannick A N Dorresteijn collaborates with scholars based in Netherlands, United Kingdom and United States. Jannick A N Dorresteijn's co-authors include Frank L.J. Visseren, Wilko Spiering, Yolanda van der Graaf, Nancy R. Cook, Arne Janssen, Xavier Rosselló, Martijn Scherrenberg, Massimo Piepoli, Eric Bonnefoy‐Cudraz and Mark Cobain and has published in prestigious journals such as JAMA, Circulation and SHILAP Revista de lepidopterología.
In The Last Decade
Jannick A N Dorresteijn
63 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jannick A N Dorresteijn Netherlands | 19 | 536 | 326 | 306 | 205 | 161 | 71 | 1.2k | ||
| Louise Bowman United Kingdom | 18 | 524 1.0× | 263 0.8× | 210 0.7× | 222 1.1× | 113 0.7× | 52 | 1.3k | ||
| Francisco Javier Félix-Redondo Spain | 19 | 611 1.1× | 303 0.9× | 376 1.2× | 82 0.4× | 229 1.4× | 63 | 1.4k | ||
| Daniel Fernández‐Bergés Spain | 20 | 689 1.3× | 337 1.0× | 378 1.2× | 81 0.4× | 271 1.7× | 79 | 1.5k | ||
| Luca Degli Esposti Italy | 20 | 540 1.0× | 299 0.9× | 318 1.0× | 295 1.4× | 190 1.2× | 200 | 1.7k | ||
| Fernando Rigo Spain | 16 | 576 1.1× | 196 0.6× | 350 1.1× | 70 0.3× | 166 1.0× | 19 | 1.1k | ||
| Diego Vanuzzo Italy | 17 | 816 1.5× | 241 0.7× | 202 0.7× | 129 0.6× | 297 1.8× | 40 | 1.5k | ||
| John K. Ninomiya United States | 3 | 317 0.6× | 294 0.9× | 406 1.3× | 80 0.4× | 238 1.5× | 5 | 993 | ||
| Lorenza Pilotto Italy | 18 | 438 0.8× | 183 0.6× | 228 0.7× | 103 0.5× | 155 1.0× | 44 | 896 | ||
| María Jesús Guembe Spain | 15 | 470 0.9× | 204 0.6× | 385 1.3× | 59 0.3× | 199 1.2× | 23 | 1.1k | ||
| Diego Vanuzzo Italy | 21 | 631 1.2× | 216 0.7× | 286 0.9× | 104 0.5× | 202 1.3× | 69 | 1.4k |
Countries citing papers authored by Jannick A N Dorresteijn
Since
Specialization
Citations
This map shows the geographic impact of Jannick A N Dorresteijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jannick A N Dorresteijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jannick A N Dorresteijn more than expected).
Fields of papers citing papers by Jannick A N Dorresteijn
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jannick A N Dorresteijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jannick A N Dorresteijn. The network helps show where Jannick A N Dorresteijn may publish in the future.
Co-authorship network of co-authors of Jannick A N Dorresteijn
This figure shows the co-authorship network connecting the top 25 collaborators of Jannick A N Dorresteijn. A scholar is included among the top collaborators of Jannick A N Dorresteijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jannick A N Dorresteijn. Jannick A N Dorresteijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hageman, Steven H J, Stephen Kaptoge, Lisa Pennells, et al.. (2025). Using SCORE2 with a risk chart or online calculator: impact on model performance, treatment eligibility, and cardiovascular disease prevention. European Heart Journal - Quality of Care and Clinical Outcomes. 12(2). 213–220.
2.
Schouw, Yvonne T. van der, Johanna M. Geleijnse, Jannick A N Dorresteijn, et al.. (2025). The relationship between the EAT-Lancet dietary pattern and risk of cardiovascular events in patients with established cardiovascular disease. European Journal of Nutrition. 64(8). 324–324.
3.
Hageman, Steven H J, Sofian Johar, Frank L.J. Visseren, et al.. (2025). SCORE2 Asia-Pacific: a comprehensive approach to prevention of cardiovascular disease. European Heart Journal. 46(17). 1682–1684.
4.
Nissen, Steven E., Qiuqing Wang, Stephen J. Nicholls, et al.. (2024). Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a). JAMA. 332(23). 1992–1992.
5.
Hageman, Steven H J, Björn Eliasson, Naveed Sattar, et al.. (2024). Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model. Diabetes Obesity and Metabolism. 26(6). 2229–2238.
6.
Carrier, Marc, Alexander T. Cohen, John‐Bjarne Hansen, et al.. (2024). Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial. Research and Practice in Thrombosis and Haemostasis. 8(7). 102569–102569.
7.
Hageman, Steven H J, Laurens van Gestel, Tobias Bonten, et al.. (2024). From reactive to proactive preventive cardiovascular risk management in primary care: a feasibility study. European Journal of Preventive Cardiology. 31(Supplement_1).
8.
Burger, P.M., Aruna D. Pradhan, Jannick A N Dorresteijn, et al.. (2023). C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations. The American Journal of Cardiology. 197. 13–23.
9.
Hageman, Steven H J, Carmen Petitjean, Lisa Pennells, et al.. (2023). Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. European Journal of Preventive Cardiology. 30(15). 1705–1714.
10.
Snaterse, Marjolein, S. Matthijs Boekholdt, Wilma J.M. Scholte op Reimer, et al.. (2023). External validation of Systematic COronary Risk Evaluation 2 - Older Persons (SCORE2-OP) in the EPIC-Norfolk prospective population study. European Journal of Preventive Cardiology. 30(Supplement_1).
11.
Snaterse, Marjolein, S. Matthijs Boekholdt, Wilma J.M. Scholte op Reimer, et al.. (2023). Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort. European Journal of Preventive Cardiology. 31(2). 182–189.
12.
May, Anne M., Martin Halle, Jannick A N Dorresteijn, et al.. (2023). Physical exercise volume, type, and intensity and risk of all-cause mortality and cardiovascular events in patients with cardiovascular disease: a mediation analysis. European Heart Journal Open. 3(3). oead057–oead057.
13.
Burger, P.M., Stefan Koudstaal, Jannick A N Dorresteijn, et al.. (2023). Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease. International Journal of Cardiology. 379. 66–75.
14.
Hageman, Steven H J, Stephanie H. Read, Taylor Owen, et al.. (2022). Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). European Journal of Preventive Cardiology. 30(1). 61–69.
15.
Read, Stephanie H., Naveed Sattar, Stefan Franzén, et al.. (2022). Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology. 17(12). 1783–1791.
16.
Visseren, Frank L.J., Yolanda van der Graaf, Yvo M. Smulders, et al.. (2021). Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. BMJ Open. 11(7). e041673–e041673.
17.
Hageman, Steven H J, Jannick A N Dorresteijn, Michiel L. Bots, et al.. (2021). Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology. 29(4). 635–644.
18.
Visseren, Frank L.J., et al.. (2018). Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. BMJ Open. 8(5). e021309–e021309.
19.
Vries, Tamar I. de, Ruth Peters, Nigel Beckett, et al.. (2018). 114Estimating individual cardiovascular disease risk reduction by blood pressure lowering in elderly patients: results from the HYVET study. European Heart Journal. 39(suppl_1).
20.
Dorresteijn, Jannick A N, et al.. (2012). Patient education for preventing diabetic foot ulceration (Review).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Louise Bowman Breakdown of academic impact, for papers by Francisco Javier Félix-Redondo Breakdown of academic impact, for papers by Daniel Fernández‐Bergés Breakdown of academic impact, for papers by Luca Degli Esposti Breakdown of academic impact, for papers by Fernando Rigo Breakdown of academic impact, for papers by Diego Vanuzzo Breakdown of academic impact, for papers by John K. Ninomiya Breakdown of academic impact, for papers by Lorenza Pilotto Breakdown of academic impact, for papers by María Jesús Guembe Breakdown of academic impact, for papers by Diego Vanuzzo